Related Experiment Video
Updated: Jun 24, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Allosterically activating SHP2 by oleanolic acid inhibits STAT3-Th17 axis for ameliorating colitis
1State Key Laboratory of Pharmaceutical Biotechnology, Nanjing Drum Tower Hospital, School of Life Sciences, Nanjing University, Nanjing 210093, China.
Abstract:
Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2) is an essential tyrosine phosphatase that is pivotal in regulating various cellular signaling pathways such as cell growth, differentiation, and survival. The activation of SHP2 has been shown to have a therapeutic effect in colitis and Parkinson's disease. Thus, the identification of SHP2 activators and a complete understanding of their mechanism is required. We used a two-step screening assay to determine a novel allosteric activator of SHP2 that stabilizes it in an open conformation. Oleanolic acid was identified as a suitable candidate. By binding to R362, K364, and K366 in the active center of the PTP domain, oleanolic acid maintained the active open state of SHP2, which facilitated the binding between SHP2 and its substrate. This oleanolic acid-activated SHP2 hindered Th17 differentiation by disturbing the interaction between STAT3 and IL-6Rα and inhibiting the activation of STAT3. Furthermore, via the activation of SHP2 and subsequent attenuation of the STAT3-Th17 axis, oleanolic acid effectively mitigated colitis in mice. This protective effect was abrogated by SHP2 knockout or administration of the SHP2 inhibitor SHP099. These findings underscore the potential of oleanolic acid as a promising therapeutic agent for treating inflammatory bowel diseases.
Insights
Oleanolic acid activates Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2), inhibiting inflammatory Th17 cell differentiation and mitigating colitis in mice.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2) is crucial for cell signaling, with therapeutic potential in inflammatory diseases.
- Identifying SHP2 activators and understanding their mechanisms is essential for developing new treatments.
Purpose of the Study:
- To identify novel allosteric activators of SHP2.
- To elucidate the mechanism of SHP2 activation by oleanolic acid.
- To evaluate the therapeutic potential of oleanolic acid in colitis models.
Main Methods:
- A two-step screening assay was employed to identify SHP2 activators.
- The binding site and conformational changes induced by oleanolic acid were analyzed.
- The effect of oleanolic acid on Th17 differentiation and STAT3 activation was investigated.
- Colitis was induced in mice to assess the therapeutic efficacy of oleanolic acid, with SHP2 knockout and inhibitor controls.
Main Results:
- Oleanolic acid was identified as a novel allosteric activator of SHP2, stabilizing its open conformation.
- Oleanolic acid binds to specific residues (R362, K364, K366) in the PTP domain, facilitating substrate interaction.
- Activated SHP2 by oleanolic acid inhibited STAT3 activation and Th17 cell differentiation by disrupting the STAT3-IL-6Rα interaction.
- Oleanolic acid treatment significantly ameliorated colitis in mice, an effect dependent on SHP2 activity.
Conclusions:
- Oleanolic acid is a potent SHP2 activator with a defined mechanism of action.
- SHP2 activation by oleanolic acid provides a novel therapeutic strategy for inflammatory bowel diseases.
- Oleanolic acid demonstrates significant potential as a treatment for colitis.
Related Concept Videos
The JAK-STAT Signaling Pathway
Drugs for Treatment of Ulcerative Colitis in IBD
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Amplifying Signals via Enzymatic Cascade
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
PI3K/mTOR/AKT Signaling Pathway

